Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Role of Bone Marrow Niche in Haematological Cancers
share announcement

Role of Bone Marrow Niche in Haematological Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 4559

Special Issue Editor

Dr. Jehan J. El-Jawhari

E-Mail Website
Guest Editor
Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK
Interests: cellular biology; mesenchymal stem cells; bone marrow microenvironment; cancer immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Blood cancers include leukaemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative syndromes.  These cancers are extremely challenging with great patient variability in molecular and clinical profiles. The treatment failure and adverse side effects of intensive therapies, particularly bone marrow transplantation, are other demands to increase research in this field. Bone marrow niches for these haematological cancers include different cells of blood and stromal types. Many genetics and functional cell studies have focused on malignant blast cells and cancer immunology. However, there is a need for novel research to understand the complicated pathogenesis of these cancers and identify new roles of related molecules and signalling.  Such knowledge is needed to improve current treatment options and develop new therapeutic tools.

This Special Issue will cover a wide range of research on the cellular and molecular mechanisms of blood cancers, particularly those taking place within the bone marrow microenvironment. We welcome submissions of original research or review articles on, but not limited to, the following topics:

  • Immune, stromal, and hematopoietic malignant cellular interactions.
  • Molecules within the bone marrow microenvironment.
  • Oncogenic pathways in bone marrow driving blood cancer progress.
  • Biotechnology, therapeutic tools, or biomaterials to model or target the blood cancer microenvironment.

Dr. Jehan J. El-Jawhari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood cancers
  • bone marrow
  • microenvironment
  • immune stromal interactions
  • mesenchymal stem cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 831 KiB  
Article
Blood Serum from Patients with Acute Leukemia Inhibits the Growth of Bone Marrow Multipotent Mesenchymal Stromal Cells
by Nataliya Petinati, Aleksandra Sadovskaya, Irina Shipounova, Alena Dorofeeva, Nina Drize, Anastasia Vasilyeva, Olga Aleshina, Olga Pokrovskaya, Larisa Kuzmina, Sofia Starchenko, Valeria Surimova, Yulia Chabaeva, Sergey Kulikov and Elena Parovichnikova
Biomedicines 2025, 13(5), 1265; https://doi.org/10.3390/biomedicines13051265 - 21 May 2025
Viewed by 419
Abstract
Background/Objectives: Acute leukemia (AL) alters both hematopoiesis and the bone marrow stromal microenvironment. Attempts to develop a culture of multipotent mesenchymal stromal cells (MSCs) from AL patients’ bone marrow are not always successful, as opposed to healthy donors’ bone marrow. Methods: [...] Read more.
Background/Objectives: Acute leukemia (AL) alters both hematopoiesis and the bone marrow stromal microenvironment. Attempts to develop a culture of multipotent mesenchymal stromal cells (MSCs) from AL patients’ bone marrow are not always successful, as opposed to healthy donors’ bone marrow. Methods: To unveil the reason, healthy donors’ MSCs were cultured in the presence of sera from healthy donors (control group) or AL patients at the onset of the disease, in short- and long-term remission, and before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: The cell yield in the presence of patient sera was lower than in the control, regardless of the AL stage. It was assumed that the patients either lacked growth factors to sustain MSCs, or there were inhibitors of MSC growth present. The serum’s ability to support MSC growth correlated with platelet count and albumin and calcium concentrations in patients’ blood. Platelet-derived growth factors—PDGFA and PDGFB—are known to induce MSC growth. Their concentration in the serum of AL patients and healthy donors was analyzed. A decrease in PDGFA concentration was found in the sera of patients compared to healthy donors. PDGFB concentration was lower at disease onset, increased during remission and decreased again during relapse. PDGFB concentration correlated with platelet count, while PDGFA concentration did not. AL patients’ sera reflected systemic disturbances affecting MSC growth. So far, decreases in PDGFs, albumin and calcium concentration, as well as platelet count, are the parameters that might be among the causes of this observation. Full article
(This article belongs to the Special Issue Role of Bone Marrow Niche in Haematological Cancers)
►▼ Show Figures

Figure 1

13 pages, 1456 KiB  
Article
Hematological and Biochemical Characteristics Associated with Cytogenetic Findern Alterations in Adult Patients with Acute Lymphoblastic Leukemia (ALL) from the Northern Region of Brazil
by Dejair da Silva Duarte, Eliel Barbosa Teixeira, Marcelo Braga de Oliveira, Thiago Xavier Carneiro, Lucyana Barbosa Cardoso Leão, Fernando Augusto Rodrigues Mello Júnior, Debora Monteiro Carneiro, Patricia Ferreira Nunes, Amanda Cohen-Paes, Diego Di Felipe Ávila Alcantara, André Salim Khayat and Rommel Mario Rodriguez Burbano
Biomedicines 2024, 12(12), 2739; https://doi.org/10.3390/biomedicines12122739 - 29 Nov 2024
Viewed by 1166
Abstract
Acute lymphoblastic leukemia (ALL) is an aggressive neoplasm derived from B and/or T cell lineage (B-ALL; T-ALL). For the first time, this study describes, cytogenetically, the karyotypic alterations in adults with ALL in the northern region of Brazil and their relationship with hematological [...] Read more.
Acute lymphoblastic leukemia (ALL) is an aggressive neoplasm derived from B and/or T cell lineage (B-ALL; T-ALL). For the first time, this study describes, cytogenetically, the karyotypic alterations in adults with ALL in the northern region of Brazil and their relationship with hematological and biochemical characteristics. Through banding analyses, immunophenotyping, as well as hematological and biochemical examination data obtained directly from patients’ records, we found that chromosome 21 aneuploidy was the most frequent. The cytogenetic structural alterations observed with the highest incidence among the patients were: t(9;22), t(4;11), t(1;19), del(6q), and del(9p). In patients presenting with chromosome alterations, we verified that patients with t(4;11) have elevated red blood cell levels and patients with del(9p) presented with distinct and high values of hematological parameters compared to other patients. Regarding biochemical alterations, we observed that patients with translocations (4;11) and del(6q) presented with elevated urea levels compared to other patients, highlighting its relationship to kidney changes and patient prognosis. Thus, our study highlights that variations in hematological and biochemical data are associated with specific cytogenetic changes and other factors, which may impact the prognosis of adult patients with ALL. Full article
(This article belongs to the Special Issue Role of Bone Marrow Niche in Haematological Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 3239 KiB  
Review
Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia
by Ilayda Eroz, Prabneet Kaur Kakkar, Renal Antoinette Lazar and Jehan El-Jawhari
Biomedicines 2024, 12(8), 1677; https://doi.org/10.3390/biomedicines12081677 - 26 Jul 2024
Viewed by 1963
Abstract
Mesenchymal stem cells (MSCs) are one of the main residents in the bone marrow (BM) and have an essential role in the regulation of haematopoietic stem cell (HSC) differentiation and proliferation. Myelodysplastic syndromes (MDSs) are a group of myeloid disorders impacting haematopoietic stem [...] Read more.
Mesenchymal stem cells (MSCs) are one of the main residents in the bone marrow (BM) and have an essential role in the regulation of haematopoietic stem cell (HSC) differentiation and proliferation. Myelodysplastic syndromes (MDSs) are a group of myeloid disorders impacting haematopoietic stem and progenitor cells (HSCPs) that are characterised by BM failure, ineffective haematopoiesis, cytopenia, and a high risk of transformation through the expansion of MDS clones together with additional genetic defects. It has been indicated that MSCs play anti-tumorigenic roles such as in cell cycle arrest and pro-tumorigenic roles including the induction of metastasis in MDS and leukaemia. Growing evidence has shown that MSCs have impaired functions in MDS, such as decreased proliferation capacity, differentiation ability, haematopoiesis support, and immunomodulation function and increased inflammatory alterations within the BM through some intracellular pathways such as Notch and Wnt and extracellular modulators abnormally secreted by MSCs, including increased expression of inflammatory factors and decreased expression of haematopoietic factors, contributing to the development and progression of MDSs. Therefore, MSCs can be targeted for the treatment of MDSs and leukaemia. However, it remains unclear what drives MSCs to behave abnormally. In this review, dysregulations in MSCs and their contributions to myeloid haematological malignancies will be discussed. Full article
(This article belongs to the Special Issue Role of Bone Marrow Niche in Haematological Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop